Publications by authors named "Humberto Erick De La Torre Tarazona"
Article Synopsis
- The study evaluated the immune response to SARS-CoV-2 variants in individuals who had recovered from COVID-19, focusing on two groups based on the time elapsed since infection (1-3 months vs. 4-12 months).
- It found that recovered individuals had higher antibody levels compared to naïve participants after vaccination, especially after receiving their second dose.
- Longer intervals between infection and vaccination (more than 3 months) significantly improved the effectiveness of the immune response against various strains of the virus, highlighting the importance of timing in vaccination strategies.
Different phenotypes exhibiting no evidences of disease progression have been described in ART-naïve HIV-1 positive individuals. Long-term non progressors (LTNP) and elite controllers (EC) are low frequent examples of immunological and virological control in HIV-1 positive subjects, respectively. The combination of both phenotypes is even less frequent and studied despite being considered as models of HIV-1 functional cure.
View Article and Find Full Text PDFImmunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study.
EClinicalMedicine
August 2022
Article Synopsis
- The CombiVacS study examined the effectiveness and safety of combining two COVID-19 vaccines, ChAdOx1-S and BNT162b2, with initial results showing a robust immune response after 14 days.
- A secondary analysis tracked the immune response in 664 adults from the initial study up to 180 days, measuring both humoral (antibody levels) and cellular (T-cell response) immunity.
- By day 180, antibody levels declined significantly in both the intervention and control groups, indicating waning immunity over time, with notably lower responses to different COVID-19 variants.
Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study.
EClinicalMedicine
September 2022
Background: There is no evidence to date on immunogenic response among individuals who participated in clinical trials of COVID-19 experimental vaccines redirected to standard national vaccination regimens.
Methods: This multicentre, prospective controlled cohort study included subjects who received a COVID-19 experimental vaccine (CVnCoV)(test group, TG) - and unvaccinated subjects (control group, CG), selected among individuals to be vaccinated according to the Spanish vaccination program. All study subjects received BNT162b2 as a standard national vaccination schedule, except 8 (from CG) who received mRNA-1273 and were excluded from immunogenicity analyses.
Article Synopsis
- - The study focuses on Long-term non-progressors (LTNP) and elite controllers (EC), who naturally manage HIV-1 effectively without treatment, and aims to analyze their miRNome (the complete set of microRNAs) to understand different immune response mechanisms.
- - By comparing miRNAs from blood samples of LTNP, EC, and typical progressors before and after treatment, researchers identified 18 differentially expressed miRNAs in typical progressors and 14 in LTNP, providing insights into how LTNPs differ from those who progress with the virus.
- - Key downregulated miRNAs in LTNP, such as miR-144-3p and miR-18a-5p, are linked to
The elite controller (EC)-long term non-progressor (LTNP) phenotype represent a spontaneous and advantageous model of HIV-1 control in the absence of therapy. The transcriptome of peripheral blood mononuclear cells (PBMCs) collected from EC-LTNPs was sequenced by RNA-Seq and compared with the transcriptomes from other phenotypes of disease progression. The transcript abundance estimation combined with the use of supervised classification algorithms allowed the selection of 20 genes and pseudogenes, mainly involved in interferon-regulated antiviral mechanisms and cell machineries of transcription and translation, as the best predictive genes of disease progression.
View Article and Find Full Text PDFCertain host genetic variants, especially in the human leucocyte antigen (HLA) region, are associated with different progression of HIV-1-induced diseases and AIDS. Long term non progressors (LTNP) represent only the 2% of infected patients but are especially relevant because of their efficient HIV control. In this work we present a global analysis of genetic data in the large national multicenter cohort of Spanish LTNP, which is compared with seronegative individuals and HIV-positive patients.
View Article and Find Full Text PDF